文献速递术前评估与围术期医学疼痛医学

安乃近显著干扰急慢性疼痛患者阿司匹林的血小板抑制作用:病例对照研究

Dipyrone (metamizole) markedly interferes with platelet inhibition by aspirin in patients with acute and chronic pain: A case-control study.
PubMed 文献 · Eur J Anaesthesiol · 2017-01-01

该病例对照研究纳入27例稳定心脑血管或外周动脉疾病伴急慢性疼痛患者,联用安乃近(≥5天)与小剂量阿司匹林,另10例单用阿司匹林为对照。

要点

  • 安乃近联用小剂量阿司匹林≥5天,78%患者血小板聚集未完全抑制。
  • 联用组血小板血栓素合成显著高于单用阿司匹林组(P<0.001)。
  • 体外实验证实安乃近显著减弱阿司匹林对血小板血栓素合成的抑制。

核心结论

  • 安乃近使用5天或更长时间会削弱多数接受者小剂量阿司匹林的血小板抑制作用。

研究设计与样本

  • 病例对照研究,纳入27例稳定心脑血管或外周动脉疾病伴急慢性疼痛患者联用安乃近(≥5天)与小剂量阿司匹林,10例可比患者单用低剂量阿司匹林为对照,设置于一家欧洲大学医院中心初级保健机构。

主要发现

  • 联用安乃近与阿司匹林的患者中仅6/27观察到聚集抑制,78%患者抗血小板治疗未达完全抑制。
  • 对照组9/10患者聚集完全抑制(P < 0.001)。
  • 联用组血小板血栓素合成高于对照组(387 ± 89 vs. 7 ± 1 ng ml,P < 0.001)。
  • 体外加入阿司匹林未能抑制安乃近治疗患者富血小板血浆的聚集和血栓素合成。
  • 健康供体体外测量证实安乃近大幅降低阿司匹林对血小板血栓素合成的抑制。

临床怎么用

  • 对使用低剂量阿司匹林进行心血管二级预防的患者,处方安乃近镇痛时需考虑其可能削弱抗血小板疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonopioid analgesic drugs may interfere with platelet inhibition by aspirin. Recent in vitro and clinical studies in patients with cardiovascular disease have suggested that this pharmacodynamic interaction may also occur with dipyrone, a nonopioid analgesic popular in Europe, Asia and South America. OBJECTIVE: Dipyrone is used extensively in acute and chronic pain. This study was undertaken to provide clinical data, so far missing, on its interactions in this group of patients. DESIGN: A case-control study. SETTING: Primary care in one European university hospital centre. PATIENTS: In total, 27 patients with stable cardiovascular, cerebrovascular or peripheral arterial disease and acute or chronic pain were identified and given dipyrone for at least 5 days in combination with low-dose aspirin. In total, 10 comparable patients on low-dose aspirin alone served as controls. MAIN OUTCOME MEASURES: Platelet-rich plasma was prepared to determine arachidonic acid-induced aggregation (aggregometry) and thromboxane formation (immunoassay). Platelet sensitivity to aspirin was examined in vitro. The presence of dipyrone (metabolites) in plasma was confirmed by HPLC. Additional in vitro measurements examined the aspirin/dipyrone interaction in healthy donors. RESULTS: Inhibition of aggregation was observed in only six of 27 patients receiving aspirin with dipyrone, with absence of complete inhibition by antiplatelet therapy showing in 78% of patients. In contrast, aggregation was completely inhibited in nine of 10 control patients (P < 0.001). Platelet thromboxane synthesis was higher in patients receiving dipyrone + aspirin compared with controls (387 ± 89 vs. 7 ± 1 ng ml, P < 0.001). Aspirin added in vitro failed to inhibit aggregation and thromboxane synthesis in platelet-rich plasma from dipyrone-treated patients. In vitro measurements with blood from healthy individuals confirmed that dipyrone dramatically reduces inhibition of platelet thromboxane synthesis by aspirin. CONCLUSIONS: Dipyrone given for 5 days or longer blunts platelet inhibition by low-dose aspirin in the majority of recipients. TRIAL REGISTRATION: German Clinical Trials Register: DRKS ID DRKS00000204. Universal Trial Number (UTN): U1111-1113-3946.

来源:Eur J Anaesthesiol,查看原文。版权归原作者所有。

引用

  1. Schmitz A, Romann L, Kienbaum P, et al. Dipyrone (metamizole) markedly interferes with platelet inhibition by aspirin in patients with acute and chronic pain: A case-control study. Eur J Anaesthesiol. 2017. PMID: 28030443. doi:10.1097/EJA.0000000000000581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。